American College

Affluent Medical : 2023 financial results and update on clinical activities under development.

Retrieved on: 
Friday, May 3, 2024
Medtech, FDA, Risk, De novo, Death, Mitral regurgitation, Doctor of Philosophy, Wound healing, Mitral valve annuloplasty, Boston Scientific, Ticker, Wealth, Urinary incontinence, Woman, Christophe, Food, Neurostimulation, Myocardial infarction, Aix-en-Provence, DSM-IV codes, LCEA, Mitral valve, TAVI, Minerva, Certification, Heart, Quality assurance, System, Anatomy, Exercise, NYHA, Dry, Marketing, Clinical trial, American College, Development director, MD, Endocarditis, Medtronic, Patient, Tricuspid valve, Acquisition, Medical device

Affluent Medical : 2023 financial results and update on clinical activities under development.

Key Points: 
  • Affluent Medical : 2023 financial results and update on clinical activities under development.
  • Affluent Medical estimates that KaliosTM would avoid repeat surgery for 30-40% of patients within five years of their operation.
  • In September 2023, the Company presented interim data on 20 patients treated in five clinical centers in Europe after one year of implantation.
  • In July 2023, Affluent Medical announced the appointments of Christophe de Vregille as Chief Financial Officer and Benjamin Renault as Development Director.

Lexicon Pharmaceuticals Reports First Quarter 2024 Financial Results and Provides Business Update

Retrieved on: 
Thursday, May 2, 2024
Shift, FDA, Albuminuria, Investment, Research, Webcast, Chronic kidney disease, Endothelium, PROGRESS, American College of Cardiology, ASN, ID, AAK1, Overalls, Heart failure, Treatment, Conference, HCM, Neuropathic pain, Quality of life, Diabetes, Patient, SGLT2 inhibitor, Travel, Diabetic ketoacidosis, Obesity, CKD, Marketing, Research and development, American College, Vessel, Insulin, Diabetes management, Inhibitor, NDA, Coagulation, Administration, Society, Lexicon, Risk, Growth, Lexicon Pharmaceuticals, Pharmaceutical industry

Net sales for the quarter were $1.1 million reflecting 63 percent growth from the previous quarter.

Key Points: 
  • Net sales for the quarter were $1.1 million reflecting 63 percent growth from the previous quarter.
  • Lexicon is initiating a Phase 3 study of sotagliflozin in HCM, with an expected study start mid-year 2024.
  • Results from Two Large US Integrated Health System
    Revenues: Revenues for the first quarter of 2024 were $1.1 million, primarily from the commercialization of INPEFA.
  • Lexicon management will hold a live conference call and webcast today at 5:00 pm ET / 4:00 pm CT to review its financial and operating results and to provide a general business update.

ImpactLife prepares for increase in blood utilization during "trauma season"

Retrieved on: 
Thursday, May 2, 2024
American College, Bleeding, EMS, Weather, Blood, Friends, Death, Trauma, Best Friends Animal Society, Emergency, Video, Injury, Patient, Violence, Accident, Emergency medical services, Hospital

Warm weather correlates to an increase in outdoor activities such as mountain biking, use of all-terrain vehicles, rock climbing, and more.

Key Points: 
  • Warm weather correlates to an increase in outdoor activities such as mountain biking, use of all-terrain vehicles, rock climbing, and more.
  • This comes with a corresponding increase in patients who require immediate medical attention due to accidents, injuries, and other emergencies.
  • ImpactLife is now looking to increase appointment schedules to meet this demand and save lives.
  • To find an ImpactLife Donor Center location or mobile blood drive, call (800) 747-5401, schedule online at www.bloodcenter.org or via the ImpactLife mobile app ( www.bloodcenter.org/app ).

LTC ACO Welcomes New Chief Operating Officer

Retrieved on: 
Wednesday, April 24, 2024
Financial management, Xavier University, LTC, American College, Denison University, Accountable care organization, Amputation, Credentialing, Economics, Practice management, Long-term care, Depression, Dementia, Patient, Physician, Medicine, ACO, Disability studies, Kidney, Standard of care, Knowledge, Nursing

KENNETT SQUARE, Pa., April 24, 2024 (GLOBE NEWSWIRE) -- LTC ACO , the first Accountable Care Organization (ACO) in the U.S. exclusively dedicated to long-term care facility residents, today announced Michele Fronckiewicz has been named chief operating officer.

Key Points: 
  • KENNETT SQUARE, Pa., April 24, 2024 (GLOBE NEWSWIRE) -- LTC ACO , the first Accountable Care Organization (ACO) in the U.S. exclusively dedicated to long-term care facility residents, today announced Michele Fronckiewicz has been named chief operating officer.
  • In this role, Fronckiewicz will lead the clinician engagement, credentialing, coding compliance, and marketing teams for LTC ACO.
  • “Michele’s depth of knowledge in the areas of value-based care, payer contracting, financial management, practice management, improvement science, and revenue cycle management made her the ideal candidate for the chief operating officer position,” said Jason Feuerman, president and CEO of LTC ACO.
  • To learn more about how LTC ACO supports providers in achieving financial success and improving clinical impact, visit http://www.ltcaco.com .

Kiniksa Pharmaceuticals Reports First Quarter 2024 Financial Results and Recent Portfolio Execution

Retrieved on: 
Tuesday, April 23, 2024
American College, Investment, RESONANCE, Partnership, Webcast, Growth, Prescription, Patient, Patient satisfaction, ID, Pericarditis, Telephone, KNSA, Pharmaceutical industry

HAMILTON, Bermuda, April 23, 2024 (GLOBE NEWSWIRE) -- Kiniksa Pharmaceuticals, Ltd. (Nasdaq: KNSA) (Kiniksa), a commercial-stage biopharmaceutical company with a pipeline of immune-modulating assets designed to target a spectrum of cardiovascular and autoimmune diseases, today reported first quarter 2024 financial results and recent portfolio execution.

Key Points: 
  • – ARCALYST® (rilonacept) Q1 2024 net product revenue of $78.9 million, representing 85% year-over-year growth –
    HAMILTON, Bermuda, April 23, 2024 (GLOBE NEWSWIRE) -- Kiniksa Pharmaceuticals, Ltd. (Nasdaq: KNSA) (Kiniksa), a commercial-stage biopharmaceutical company with a pipeline of immune-modulating assets designed to target a spectrum of cardiovascular and autoimmune diseases, today reported first quarter 2024 financial results and recent portfolio execution.
  • Total revenue for the first quarter of 2024 was $79.9 million, compared to $48.3 million for the first quarter of 2023.
  • Total operating expenses for the first quarter of 2024 were $96.4 million, compared to $59.5 million for the first quarter of 2023.
  • Kiniksa will host a conference call and webcast at 8:30 a.m. Eastern Time on Tuesday, April 23, 2024, to discuss first quarter 2024 financial results and recent portfolio execution.

Dr. Bhavin Patel Joins DHAT in Bedford

Retrieved on: 
Monday, April 22, 2024
Richmond University Medical Center, American College, Liver disease, Communication, Cancer, IBD, Fecal incontinence, Patient, Health, Internal medicine, Esophageal dysphagia, IBS, Nursing

Dr. Patel is an experienced gastroenterologist affiliated with the American College of Gastroenterology, American Board of Internal Medicine, and many more.

Key Points: 
  • Dr. Patel is an experienced gastroenterologist affiliated with the American College of Gastroenterology, American Board of Internal Medicine, and many more.
  • He received his doctorate from Windsor University School of Medicine and completed his residency at Richmond University Medical Center.
  • “My patients can expect a patient-centered approach focused on providing personalized care,” says Dr. Patel.
  • DHAT is at 1600 Central Drive in Bedford, TX , and is open Monday through Friday, 8am to 5pm.

St. Vincent Regional Hospital Verified as Level I Trauma Center by American College of Surgeons

Retrieved on: 
Friday, April 19, 2024
Education, Trauma center, Nursing care plan, Injury, American College, Hospital, Intermountain, Trauma, Research, ACS, Patient, Caregiver, Trust, Rehabilitation, Resuscitation, Intermountain Health, Level 2

Billings, Montana, April 19, 2024 (GLOBE NEWSWIRE) -- Intermountain Health St. Vincent Regional Hospital is proud to announce its official verification as a Level I Trauma Center by the American College of Surgeons (ACS), marking a significant milestone in the hospital's commitment to providing top-tier emergency medical care to the community.

Key Points: 
  • Billings, Montana, April 19, 2024 (GLOBE NEWSWIRE) -- Intermountain Health St. Vincent Regional Hospital is proud to announce its official verification as a Level I Trauma Center by the American College of Surgeons (ACS), marking a significant milestone in the hospital's commitment to providing top-tier emergency medical care to the community.
  • “We have worked diligently to meet the stringent criteria set forth by the ACS for Level I Trauma Centers.
  • From initial resuscitation and emergency surgery to intensive care and rehabilitation, St. Vincent is equipped to provide the full spectrum of trauma care," said Dr. Barry McKenzie, trauma medical director at St. Vincent.
  • Qualifications of a Level I Trauma Center verification through the ACS include:
    Comprehensive care for critically injured patients, from prevention through rehabilitation
    St. Vincent is one of two hospitals in Montana and one of two hospitals in the Intermountain Health system to achieve Level I Trauma Center verification from the ACS.

Dr. Dushyant Singh Joins AGA in Tulsa

Retrieved on: 
Friday, April 19, 2024
University, Gastroenterology, American College, University of Missouri, Fellow, Patient, Associate, Health, OK, Knowledge, Nursing

Tulsa, OK, April 19, 2024 (GLOBE NEWSWIRE) -- With more than a decade of experience, Adult Gastroenterology Associates is excited to announce the addition of Dr. Dushyant Singh, a physician passionate about treating all gastrointestinal diseases using his knowledge about nutrition holistically to apply the latest advancements with Eastern wisdom healing principles.

Key Points: 
  • Tulsa, OK, April 19, 2024 (GLOBE NEWSWIRE) -- With more than a decade of experience, Adult Gastroenterology Associates is excited to announce the addition of Dr. Dushyant Singh, a physician passionate about treating all gastrointestinal diseases using his knowledge about nutrition holistically to apply the latest advancements with Eastern wisdom healing principles.
  • Dr. Singh hails from India, holds an honorable Fellowship in the American College of Physicians distinction and received his doctorate from University of Missouri before completing his residency and fellowship at same.
  • “I am very excited to join this amazing team,” says Dr. Singh.
  • AGA is at 4200 East Skelly Drive in Tulsa, OK , and is open Monday through Friday, 8 a.m. to 4:30 p.m.

When Emergency Physicians Regularly Fear Violence at Work, It’s Past Time for Change

Retrieved on: 
Tuesday, April 16, 2024
Congress, Gun, American College, Safety, Emergency medicine, MD, Conference, Research, Emergency, Weapon, SAVE, Patient, Legislation, Occupational safety and health, Physician, FACEP, ACEP, Workforce, OSHA, Nursing

“When our status quo involves daily fear of assault, it’s time for change,” said Aisha Terry, MD, FACEP, president of ACEP.

Key Points: 
  • “When our status quo involves daily fear of assault, it’s time for change,” said Aisha Terry, MD, FACEP, president of ACEP.
  • “Emergency physicians have to be able to focus on caring for patients, without fearing for their safety.
  • In fact, nearly three-quarters (71%) of respondents believe that violence in the emergency department is worse than last year.
  • As part of the polling, ACEP gathered more than 800 troubling stories directly from emergency physicians.

New Studies Prove the Clinical Benefits of Daxor’s Blood Volume (BVA-100TM) Diagnostic In Ambulatory Heart Failure Patients For Measurement of Congestion

Retrieved on: 
Tuesday, April 16, 2024
Duke University Hospital, American Heart Journal, American College, Congestion, Research, Baptist Memorial Hospital, Proxy, Heart failure, Pressure, Patient, BVA, Volume analysis, Letter, HF, Systemic, Medical imaging

Oak Ridge, TN, April 16, 2024 (GLOBE NEWSWIRE) -- Daxor Corporation (Nasdaq: DXR), the global leader in blood volume measurement technology, today announces two new studies validating the clinical benefits of blood volume analysis (BVA) as a more precise measurement of congestion in ambulatory heart failure (HF) patients. Data from both studies demonstrated a lack of correlation between surrogate measures and actual blood volume, highlighting the necessity for accurate volume measurement, as provided by BVA.

Key Points: 
  • Data Presented at the American College of Cardiology Scientific Sessions;
    Oak Ridge, TN, April 16, 2024 (GLOBE NEWSWIRE) -- Daxor Corporation (Nasdaq: DXR), the global leader in blood volume measurement technology, today announces two new studies validating the clinical benefits of blood volume analysis (BVA) as a more precise measurement of congestion in ambulatory heart failure (HF) patients.
  • Data from both studies demonstrated a lack of correlation between surrogate measures and actual blood volume, highlighting the necessity for accurate volume measurement, as provided by BVA.
  • “These studies add to the numerous research papers and trials reporting the value of BVA at measuring congestion to improve outcomes,” stated Jonathan Feldschuh, Daxor’s Chief Scientific Officer.
  • A research letter published in the American Heart Journal, titled, ‘Prognostic Implications of Volume Status Assessed by Blood Volume Analysis in Ambulatory Heart Failure,’ was authored by leading heart failure experts from Duke University Medical Center, Baptist Memorial Hospital and Banner University Medical Center.